Product Program year 2019 Source: CMS Open Payments

Fluzone High-Dose

Drug Vaccines

NDC 49281-405-65

Open in the dashboard

General payments

$569,650

12,743 payments

Research payments

$325,520

8 payments

Through program year 2019, $569,650 in general payments and $325,520 in research payments were reported against Fluzone High-Dose (Vaccines).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2019 General $569,650 12,743
2019 Research $325,520 8

Breakdown

Who paid General payments · program year 2019
  1. Sanofi Pasteur Inc. $568,190 12,728 payments
  2. Sanofi-Aventis U.S. LLC $1,446 14 payments
  3. Vaxserve Inc. $14 1 payment
Top recipients General payments · program year 2019
  1. Christopher Belcher Pediatric Infectious Diseases · Carmel, IN $42,103 7% · 91 payments
  2. Marvin Bittner Infectious Disease · Omaha, NE $36,999 6% · 78 payments
  3. Robert Belshe Infectious Disease · Saint Louis, MO $35,174 6% · 42 payments
  4. Peter Sebeny Infectious Disease · Newburyport, MA $34,632 6% · 45 payments
  5. Mohammad Madjid Interventional Cardiology · Ventura, CA $23,110 4% · 20 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2019.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2019
  1. Family Medicine $186,175 33% · 4,883 practitioners
  2. Infectious Disease Internal Medicine $160,326 28% · 68 practitioners
  3. Internal Medicine $94,530 17% · 3,171 practitioners
  4. Pediatric Infectious Diseases Pediatrics $51,183 9% · 4 practitioners
  5. Interventional Cardiology Internal Medicine $23,348 4% · 13 practitioners

The top 5 of 98 specialties; each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2019
  1. Indiana $69,395 12% · 265 recipients
  2. Texas $63,563 11% · 842 recipients
  3. California $58,962 10% · 1,295 recipients
  4. Missouri $40,954 7% · 325 recipients
  5. Nebraska $38,586 7% · 92 recipients

The top 5 of 52 states; each share is of general payments naming this product in 2019 where a state was reported.

The top 25 states, free in the app

12,743 general · 8 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2019

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record